Healthcare Industry News: Flagship Ventures
News Release - September 24, 2007
Acceleron Pharma Appoints Niels Borgstein, M.D. as Vice President, Medical Research
CAMBRIDGE, Mass.--(HSMN NewsFeed)--Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that Niels Borgstein, M.D. has joined Acceleron as Vice President, Medical Research. Dr. Borgstein has more than 10 years of international clinical research and development experience in the pharmaceutical industry, ranging from exploratory/first-in-human clinical studies to full development projects.Prior to joining Acceleron, Dr. Borgstein served as a clinical consultant at Dynogen Inc. From 1998 to 2006, Dr. Borgstein worked at Pfizer Inc., both in Sandwich, UK and Groton/New London, Conn., serving as Director with increasing responsibilities covering multiple therapeutic areas including bone, urology, sexual health and gastrointestinal related diseases. During the last two years with Pfizer, Dr. Borgstein was Global Clinical Lead for its bone/fracture healing program. Dr. Borgstein received his M.D. and Orthopedic Surgery training from the University Hospital of Groningen in The Netherlands.
"The positive phase 1 study results from our lead bone program, ACE-011, were presented at the American Society of Bone Mineral Research Annual Meeting in Honolulu last week, and we are preparing to initiate a Phase 2 trial later this year," said Matthew Sherman, M.D., Chief Medical Officer. "Niels' extensive experience in clinical development in bone health and other therapeutic areas will add substantial value to the development of Acceleron's product portfolio."
"I am delighted to join Acceleron and be a part of such a great team," said Dr. Borgstein. "We are preparing to start several exciting clinical studies including the ACE-011 phase 2 study and the phase 1 study for our lead muscle program, ACE-031. I am thrilled to join an organization that is developing novel products targeting diseases with enormous unmet medical need."
About Acceleron Pharma
Acceleron is a privately held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel biotherapeutics that modulate the growth of bone, muscle, fat and the vasculature to treat musculoskeletal, metabolic and cancer-related diseases. Acceleron's scientific approach takes advantage of its unique insight into the regenerative powers of two protein families: the Growth and Differentiation Factors (GDFs) and Bone Morphogenetic Proteins (BMPs). ACE-011, a novel bone forming agent, is the company's lead program, and is being developed to reverse bone loss in diseases such as cancer-related bone loss. In addition, the company is advancing through preclinical development product candidates that increase muscle mass, control angiogenesis and inhibit fat accumulation. Acceleron utilizes proven biotherapeutic technologies and capitalizes on the company's internal GMP manufacturing capability to rapidly and efficiently advance its therapeutic programs. The investors in Acceleron are Advanced Technology Ventures, Flagship Ventures, OrbiMed Advisors, Polaris Ventures, Sutter Hill Ventures and Venrock.
Source: Acceleron Pharma
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
